Genflow Biosciences

Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. The company was incorporated in 2021 and is headquartered in London, the United Kingdom.

At Genflow Biosciences, our mission is to develop and manufacture innovative therapeutic enzymes and proteins to improve the lives of those dealing with rare diseases.

Our vision is to be the leader in developing and manufacturing therapeutic enzymes and proteins for rare diseases and to empower patients with greater independence and health.

Genflow Biosciences has earned numerous awards for our research and development of therapeutic enzymes and proteins for rare disease treatments. These awards include the CIRM Therapeutic Innovation Awards in 2011, the ASTs Biotherapeutics Award in 2012, and the BioNJ Developing Therapeutics Award in 2013.